{"disease":{"id":"naloxone","name":"naloxone"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06523985","title":"The Feasibility of Using the PulsePoint to Facilitate Overdose Education and Naloxone Distribution","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":5000,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT06429436","title":"Vending Machine Naloxone Distribution for Your Community (VENDY)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT04025671","title":"A Usability Assessment of Naloxone Administration by Untrained Community Members","phase":"NA","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"State University of New York - Upstate Medical University","has_results":false},{"nct_id":"NCT03430180","title":"Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":126,"lead_sponsor_name":"Finnish Institute for Health and Welfare","has_results":false},{"nct_id":"NCT04303000","title":"Increasing Naloxone Access for Persons Who Use Opioids","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true},{"nct_id":"NCT02516059","title":"Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural Analgesia","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT04677387","title":"Nalox-Comm: Naloxone Communication Training for Pharmacists","phase":"NA","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":true},{"nct_id":"NCT03223896","title":"Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Finnish Institute for Health and Welfare","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}